DALLAS, Feb. 4, 2010 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Cyclacel Pharmaceuticals Inc. (Nasdaq:CYCC). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.investorsoup.com/lp/CYCC
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup">www.twitter.com/investorsoup
Cyclacel Pharmaceuticals Inc. (CYCC) is a development-stage biopharmaceutical company engaged in the discovery, development and commercialization of mechanism-targeted drugs to treat human cancers and other serious disorders. The Company markets, directly in the United States, Xclair Cream for radiation dermatitis, and Numoisyn Liquid and Numoisyn Lozenges for xerostomia through its wholly owned subsidiary, ALIGN Pharmaceuticals LLC. CYCC focuses primarily on the development of orally available anticancer agents that target the cell cycle with the aim of slowing the progression or shrinking the size of tumors.
Message Board Search for CYCC: http://www.boardcentral.com/boards/CYCC
In the report, the analyst notes:
"Total revenues for the third quarter of 2009 were $0.2 million representing a decrease of 14% compared to $0.3 million for the same period in 2008. These revenues were mainly attributable to sales of the Xclair® and Numoisyn® products.
"CYCC in early January announced the publication of two peer-reviewed journal articles featuring the Company's seliciclib (CYC202 or R-roscovitine) drug candidate, an orally available inhibitor of multiple cyclin-dependent kinases (CDKs). CDKs have been extensively investigated as therapeutic targets in light of their frequent deregulation in lung carcinogenesis. In an article published in Clinical Cancer Research, seliciclib was found to be effective in killing lung cancer cells through a novel apoptotic mechanism or induction of cancer cell suicide. Nearly all lung cancer cell lines against which seliciclib was most effective had Ras-activating mutations. Ras is a family of mutations which make lung cancer cells highly resistant to approved drugs such as those targeting epidermal growth factor receptors (EGFR)."
To read the entire report visit: http://www.investorsoup.com/lp/CYCC
See what investors say about CYCC at penny stock forum
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit www.InvestorSoup.com/">http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither InvestorSoup nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.